MME and endothelial dysfunction: The dual neprilysin inhibitor sacubitril and ang II type 1 receptor blocker valsartan combined drug sacubitril/valsartan (LCZ696) suppresses the neprilysin and ang II receptor at the same time and exerts beneficial effects on endothelial dysfunction, cardiac dysfunction, hypertension, HF, ischemic brain damage and cardiovascular ischemia–reperfusion injury in experimental and clinical investigations4,7,9.